Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation
PDF | HTML | How to cite
Metrics: PDF 1851 views | HTML 2436 views | ?
Takayuki Kimura1,2, Makoto Sugaya1,2, Tomonori Oka1,2, Andrew Blauvelt3, Hitoshi Okochi2, Shinichi Sato1
1Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
2Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
3Oregon Medical Research Center, Portland, Oregan, USA
Makoto Sugaya, e-mail: [email protected]
Keywords: lymphatics, lymphedema, tumor immunity, cytotoxic T cells
Received: March 18, 2015 Accepted: May 11, 2015 Published: May 27, 2015
Tumor growth and metastasis of cancer involve autonomous tumor cell growth and host-tumor interactions. While tumor-specific immunity has been intensively studied in vitro, dynamic roles of lymphatic transport on tumor immunity in vivo have not been fully elucidated. In this study, we examined tumor growth and anti-tumor immune responses using kCYC mice, which demonstrate severe lymphatic dysfunction. Primary tumor growth was augmented in kCYC mice (compared to wild-type mice) when B16 melanoma or EL-4 lymphoma cells were subcutaneously injected. Expression of inflammatory cytokines such as IFN-γ, TNF-α, and IL-2 as well as IL-10 expression in draining lymph nodes (LNs) was significantly reduced in kCYC mice after tumor inoculation. Moreover, decreased levels of tumor-associated antigens were detected in draining LNs in kCYC mice, together with impaired antigen presentation. CD8+ T cells in draining LNs derived from kCYC mice bearing B16 melanoma also showed significantly decreased cytotoxic activity in vitro. Finally, tumor suppression activity of CD8+ T cells derived from kCYC mice bearing B16 melanoma was reduced when adoptively transferred to naive wild-type mice. In summary, these findings suggest that lymphatic transport is essential in generating optimal tumor-specific immune responses mediated by CD8+ T cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.